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Background: The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell
lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high dose
therapy followed with autologous stem cell transplantation. In the rituximab era however, this treatment approach
has shown only limited benefit. In particular, patients relapsing after rituximab-containing primary treatment have
an adverse prognosis, especially if this occurs within the first year after therapy or if the disease is primarily
refractory. Therefore there is an ultimate need for improved salvage treatment approaches.
Methods/design: The STORM study is a prospective, multicentre phase I/II study to evaluate the safety, feasibility
and activity of salvage therapy consisting of the mTOR inhibitor temsirolimus added to the standard therapy
rituximab and DHAP for the treatment of patients with relapsed or refractory DLBCL. The primary objective of the
phase I of the trial is to establish the maximum tolerated dose (MTD) of temsirolimus in combination with
rituximab and DHAP. The secondary objective is to demonstrate that stem cells can be mobilized during this
regimen in patients scheduled to proceed to high dose therapy. In phase II, the previously established maximum
tolerated dose of temsirolimus will be used. The primary objective is to evaluate the overall response rate (ORR) in
patients with relapsed DLBCL. The secondary objective is to evaluate progression free survival (PFS), overall survival
(OS) and toxicity. The study will be accompanied by an analysis of lymphoma subtypes determined by gene
expression analysis (GEP).
Discussion: The STORM trial evaluates the safety, feasibility and activity of salvage therapy consisting of the mTOR
inhibitor temsirolimus added to standard therapy of rituximab and DHAP for the treatment of patients with
relapsed or refractory DLBCL. It also might identify predictive markers for this treatment modality.
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Non-Hodgkin’s Lymphomas are the fifth most common
tumor type worldwide, and their incidence is still increasing
[1]. Although in recent years advances in tumor therapy
and supportive care have improved overall survival, a large
proportion of patients will ultimately die of their disease.
The prognosis of diffuse large B-cell lymphoma (DLBCL)
has improved with the advent of the monoclonal antibody
rituximab. However, there is increasing evidence that
treatment of patients with relapsed and refractory disease
remains challenging. The current standard treatment of
patients with relapsed or refractory DLBCL primarily con-
sists of intensified salvage therapy using widely accepted
regimens like R-DHAP or R-ICE. For chemo-sensitive
disease high dose therapy followed with either autologous
[2] or, in selected cases, allogeneic transplantation is
applied. In the rituximab era however, high dose therapy
and autologous transplantation have only been of limited
benefit in relapsed and refractory disease, and allogeneic
transplantation is limited to a selected small subset of
patients. The dismal prognosis was recently underlined by
the interim analysis of the CORAL trial, in which patients
with relapsed DLBCL were randomized to either receive
salvage R-DHAP or R-ICE: it was demonstrated that
patients relapsing after rituximab-containing primary
treatment had an adverse prognosis, especially if this
occured within the first year after therapy or if the dis-
ease was primarily refractory. Even with this intensive
treatment in this patient subset only 10-15% of patients
achieve long-term survival [3].
Recently, the specific mTOR inhibitor temsirolimus
has shown to be clinical active in relapsed mantle cell
lymphoma in a large multicenter phase III trial, which
included patients with up to 7 prior lines of therapy. In
this poor-risk population, the ORR was 22% using a regi-
men consisting of 175mg temsirolimus for 3 weeks given
weekly, followed by 75mg/weekly or 25mg/weekly until
tumor progression or unacceptable toxicity occured.
During the later therapy phase the average dose was
52 mg/week. The most prominent side effect in this
trial was thrombocytopenia. PFS, which was the primary
endpoint of this trial, was significantly superior using
this regimen, in comparison to a standard treatment
arm, which consisted of a variety of commonly accepted
single agents. Interestingly, the superiority of temsirolimus
appeared to be accentuated in patients with a lower num-
ber of pre-treatments [4]. In another trial, the combination
of rituximab and even low dosis of temsirolimus resulted in
impressive response rates in relapsed and refractory mantle
cell lymphoma [5].
Furthermore, a recently presented phase II trial by
Smith and colleagues demonstrated single agent activity
of temsirolimus in DLBCL and follicular lymphoma by
achieving a ORR of 56% in relapsed patients. Especially asingle agent activity of 28% in relapsed aggressive lymph-
oma is promising and merits further evaluation [6].
It seems therefore a logical consequence to incorporate
temsirolimus into earlier treatment lines or to combine
it with other therapies. Accordingly, a combination of
temsirolimus with bendamustine and rituximab achieved a
response in all patients evaluable with relapsed mantle cell
and follicular lymphoma [7]. Of note, in recent in vitro
experiments, additive action of temsirolimus, dexametha-
sone, cytarabine and platinum could be demonstrated
[8]. Building on to this, the STORM trial combines
temsirolimus with a well-established salvage treatment
protocol (R-DHAP) with a known safety profile for the
treatment of patients with refractory or relapsed DLBCL.
The aim of this trial is to determine the safety, feasibility
and clinical activity of the proposed regimen.
Methods/design
Trial organization
The STORM trial has been designed by the Trial Centre
of the Department of Hematology and Oncology of
the University of Heidelberg in cooperation with the
Department of Hematology and Oncology of the University
of Mainz and the other participating centres. The trial is
an investigator initiated trial, and is sponsored by the
University Hospital of Heidelberg. The trial is coordi-
nated by the Department of Hematology and Oncology
of the University of Heidelberg, which is responsible
for the overall trial management, trial registration
(ClinicalTrials.gov Identifier NCT01653067) and the
scientific program of all trial-related meetings. Database
management, quality assurance, monitoring and reporting
is performed by the Interdisciplinary Centre for Clinical
Trials (IZKS) at the University of Mainz.
A total of 9 German centres participate in this trial.
The centres are (listed alphabetically): University Hospital
Charité, Berlin; University Hospital Erlangen; University
Hospital Frankfurt, University Hospital Freiburg; Uni-
versity Hospital Heidelberg; University Hospital Mainz;
University Hospital Munich LMU; University Hospital
Munich TU and University Hospital Ulm.
On-site monitoring
During recruitment on-site monitoring is performed
following good clinical practice (GCP) guidelines. The data
management will be performed by the Interdisciplinary
Centre for Clinical Trials (IZKS) at the University of Mainz.
Ethics, informed consent and safety
The final protocol was jointly approved by the central eth-
ics committee of this trial at the University of Heidelberg,
Medical School (AFmu-017/2012, http://www.klinikum.
uni-heidelberg.de) and by the ethics committees of all
participating centres. This study complies with the Helsinki
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Association's professional code of conduct, the principles of
Good Clinical Practice (GCP) guidelines and the Federal
Data Protection Act. The trial will also be carried out in
keeping with local legal and regulatory requirements.
The medical secrecy and the Federal Data Protection
Act will be followed.
Informed consent is obtained from each patient in oral
and written form before inclusion in the trial and after
the nature, scope, and possible consequences of the trial
have been explained by a physician. The investigator will
refrain from any measures specifically required only for
the clinical trial until valid consent has been obtained.
Study design and objectives
The STORM study is a prospective phase I/II study to
evaluate the safety, feasibility and activity of a salvage
therapy consisting of the mTOR inhibitor temsirolimus
added to standard therapy of rituximab and DHAP for the
treatment of patients with relapsed or refractory DLBCL.
The STORM-trial consists of two phases.
Phase I is a dose-escalation study of temsirolimus.
The primary objective is to establish the maximum tol-
erated dose (MTD) of temsirolimus in combination
with rituximab and DHAP. The secondary objective is
to demonstrate that stem cells can be mobilized during
this regimen in patients scheduled to proceed to high
dose therapy.
In phase II, the previously established maximum tol-
erated dose of temsirolimus will be used. The primary
objective is to evaluate the overall response rate (ORR)
in patients with relapsed DLBCL. The secondary objective
is to evaluate progression free survival (PFS), overall
survival (OS) and toxicity.
Patient selection
To be included into the STORM trial, patients must be
at least 18 years old and have a histologically confirmed
diagnosis of DLBCL according to the World Health
Organization classification. There must be a documented
relapse or progression after at least one prior treatment
but a maximum of two prior treatments. Prior treatment
must have included at least three cycles of anthracycline-
containing chemotherapy (e.g. CHOP-like). The histology
has to be confirmed by a reference pathologist. Evaluation
of CD20 status is compulsory. At least one measurable
tumor mass (>1.5 cm x >1.0 cm), involvement of any organ
or bone marrow infiltration must be present. In addition,
adequate organ function and a Eastern Cooperative
Oncology Group [ECOG] performance Status of less
than 3 are essential for inclusion into the trial. Patients
are required to use adequate contraception before entry
and throughout the study, if appropriate. Naturally, patients
must have signed an informed consent document indicatingthat they understand the purpose of and procedures
required for the study and are willing to participate in
the study.
Patients with lymphoma other than DLBCL or active
central nervous system lymphoma are not eligible. Other
exclusion criteria are severe concomitant diseases, active
uncontrolled infections including HIV, active hepatitis B
or C or other malignant disease (except: adequately treated
non-melanoma skin cancer, curatively treated in-situ cancer
of the cervix, DCIS of the breast, or other solid tumors
curatively treated with no evidence of disease for >5 years).
Prior treatment with temsirolimus, known CD20 negativity,
disease refractory to DHAP in a prior treatment line, severe
psychiatric illness, peripheral neuropathy or neuropathic
pain grade 2 or worse, prior autologous or allogeneic stem
cell or bone marrow transplantation, concurrent treatment
with another investigational agent during the conduct
of the trial or known intolerance to sirolimus or derivates,
cytarabine, cisplatine or rituximab will prohibit inclusion,
as well as pregnancy or breast feeding.
Statistical design
In phase I of the study, a 6 + 6 standardized design is
chosen to establish the MTD of the investigational product
(temsirolimus). A maximum of 48 patients can conse-
quently be included into this phase. In phase II of the
study, 40 patients will be included, receiving two to
four cycles of the full target dose of temsirolimus in
combination with R-DHAP, as established in phase I of
the trial. The number of cycles will depend on the
evaluation of activity and toxicity of the regimen by the
investigator in each individual patient. Based on published
data on rituximab in combination with DHAP, a response
rate of at least 60 to 65% (40% CR and CRu) can be
expected. The study will be terminated if the number of
non-responders exceeds a critical value determined by
Wald´s Sequential probability ratio test. In both phases
of this trial explorative statistics are used to calculate
remission and response rates. Median progression free
survival, overall survival etc. are calculated by the
Kaplan and Meier method. Adverse events will be classified
according to MedDRA terminology. The frequency of
adverse events will be calculated, and there will be fur-
ther analyses to determine their seriousness, intensity,
duration, relationship to trial treatment, actions taken
and clinical outcome. Patients with and without con-
solidating high dose therapy and autologous stem cell
transplantation will be analysed separately.
Work up
Patients with histologically documented diagnosis of
DLBCL receive a complete work-up which includes
cervical, thoracic, abdominal and pelvic CT scans, bone
marrow histology and extensive laboratory testing. The IPI
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exclusion criteria are evaluated. If patients meet all inclu-
sion criteria, they will be informed about the study and all
associated risks and benefits, and their written consent is
sought. If patients decline treatment within the STORM
trial, an adequate alternative treatment regimen is offered.
Treatment
This is a multicenter, open label, single arm, phase I/II
study. Placebo will not be used within this trial. In phase
I, the dose escalation phase of this trial, 6 patients will
be included in each dose level. There will be four cohorts,
administering up to a maximum of four cycles with 25 mg,
50 mg, 75mg or 100mg temsirolimus on day 1 and 8 in
combination with rituximab (375 mg/m2 day 2) and DHAP
(dexamethasone 40mg day 3–6, cisplatin 100 mg/m2 day 3,
cytarabine 2 × 2 g/m2 day 4). Treatment is repeated on day
22 for up to a maximum of 4 cycles.
After inclusion of six patients, each patient has to re-
ceive at least one complete cycle without experiencing
any dose limiting toxicity, until the enrolment into the
next cohort can be initiated. In phase II of the trial 40
patients will be included to receive the previously
established full target dose. Special attention in phase I
and phase II of the study is brought to monitoring of ad-
verse events. Stem cell mobilization and subsequent high
dose therapy and autologous stem cell transplantation
can be performed in eligible patients (Figure 1).
Safety and discontinuation of treatment
Toxicities are classified by grade, type, duration, onset, and
relationship to study treatment using the NCI Common
Toxicity Criteria (CTC). Dose limiting toxicities of STORM
in the context of the trial treatment are defined as any
CTCAE grade V toxicity that are potentially related to the
trial treatment, any hematological toxicity not recovering to
at least NCI CTCAE grade II after 28 days after start of
the last STORM-cycle (except as a consequence of boneFigure 1 Treatment algorithm of the STORM trial.marrow insufficiency due to bone marrow infiltration)
and any non-hematological toxicity NCI CTCAE grade
III/IV not recovering to grade II within 14 days after initial
occurrence and potentially related to the trial treatment.
In phase I of the trial 6 patients will be included at
each dose level. After inclusion of six patients, each
patient has to receive at least one complete cycle without
experiencing any dose limiting toxicity (DLT), until the
enrolment into the next cohort can be initiated. If one
DLT occurs, this is discussed with the data safety monitor-
ing board (DSMB). The DSMB may recommend that six
additional patients will be added to the specific dose level.
If two DLTs occur in the first six patients of a cohort, six
additional patients will be added to the specific dose level
and this will be discussed with the DSMB. If three DLTs
occur in the 6 + 6 cohort, the DSMB will be informed and
will recommend further action. If a fourth DLT appears in
the 6 + 6 cohort, the last dose level with three or less than
three DLTs will be considered the standard dose for the
phase II trial. If four DLTs occur in cohort A, the study will
continue with an additional Cohort X with a temsirolimus
dose of 15 mg. If the final dose level is achieved without
any DLT, there will be no further dose escalation. Addition-
ally, cumulated data of each dose level will be presented to
the DSMB prior to proceeding to the next dose level. The
6 + 6 design was chosen to provide a more robust data
basis than a 3 + 3 design.
Trial duration
Patient recruitment is planned to be completed after 24
months. Patients will be monitored for three years after
study entry. The total duration of the trial is estimated
to be five years. Recruitment will begin in April 2013.
Assessment of therapeutic efficiency
Assessments including patient history, physical exam,
CT of neck, chest and abdomen, bone marrow biopsy
and serological tumor markers are scheduled before,
during and after treatment and during follow up.
Response is evaluated in accordance with the Cheson
Criteria [9]:
 Complete response (CR) is the complete
disappearance of all detectable evidence of disease
on CT, and all disease-related symptoms, and
normalization of biochemical abnormalities, and
normal bone marrow biopsy (BMB). Previously
involved nodes on CT more than 1.5 cm in their
greatest axial diameter must regress to less than 1.5
cm, and previously measured nodes of 1.1–1.5 cm
must decrease to less than 1 cm.
 CRu (uncertain) corresponds to CR criteria but with
a residual mass more than 1.5 cm in greatest axial
diameter that has regressed by more than 75%.
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sum of the product of the greatest diameters (SPD)
of the six largest nodes with no increase in the size
of other nodes and no new sites of disease. Splenic
and hepatic nodules must regress by at least 50% in
the SPD.
 Stable disease (SD) is less than a PR but is not
progressive disease. Progressive disease (PD) is more
than 50% increase in the sum of the product of the
greatest diameters of any previously abnormal node,
or appearance of any new lesions during or at the
end of therapy.
 Relapsed disease (RD) is the appearance of any new
lesion or increase in size of more than 50% of
previously involved sites or nodes in patients who
achieved CR or CRu.
PET-data will be collected if available upon discretion
of the individual physician.
Quality assurance program
Quality assurance, database management, monitoring and
reporting is performed by the Interdisciplinary Centre for
Clinical Trials (IZKS) at the University of Mainz.
Discussion
The STORM trial evaluates the safety, feasibility and
activity of salvage therapy consisting of the mTOR inhibitor
temsirolimus added to standard therapy of rituximab
and DHAP for the treatment of patients with relapsed
or refractory DLBCL. It also might identify predictive
markers for this treatment modality.
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